Skip to main content
OpenTrials
Completed

NCT Number: NCT05558553

Are Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Systemic Immune Inflammation Score Values Indicators for Postoperative Pain?

Postoperative pain status of patients who underwent elective laparoscopic cholecystectomy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

SAMSUN UNIVERSITY Samsun Training and research hospital, Samsun, Turkey (Türkiye)

Loading trial locations.

About this study

Subject Researched:

Postoperative pain is a result of the inflammatory response to surgical trauma. Local inflammatory mediator response triggered by surgical incision, dissection, retraction, etc. causes an increase in nociceptor sensitivity and hyperalgesia, resulting in the perception of postoperative pain. With the acute phase response caused by surgical trauma, tissue damage is brought under control, infection is limited and the healing process begins. During the inflammatory response, the level of leukocytes in the blood also changes. Neutrophil/Lymphocyte ratio (NLR), Platelet/Lymphocyte ratio (PLR) and Systemic immune inflammation score (SII) are inexpensive and easily accessible biomarkers calculated from routine hemogram parameters and shown to be helpful in disease investigations and evaluation of treatment response. In this study, the relationship between biomarkers and postoperative pain status due to surgery will be investigated

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18-75 years who underwent elective laparoscopic cholecystectomy.
  • Patients with ASA status1-2-3

Exclusion criteria

  • Emergency operated patients
  • Patients switched to open surgery
  • Patients allergic to tramadol
  • Those allergic to paracetamol
  • Those allergic to tenoxicam
  • Patients who cannot use the patient-controlled analgesia device
  • Those with hematological disorders
  • Those receiving immunosuppressive therapy
  • Those with inflammatory disease
  • Those with gastrointestinal tumors
  • Those with rheumatic disease
  • Those with uncontrolled diabetes
  • Those with chronic organ failure
  • Those who use corticosteroids
  • Opioid users
  • Those who have recently had an attack of cholecystitis, pancreatitis

Treatment and study plan

Primary outcomes

  1. postoperative analgesic consumption

    Time frame: 24 hours

Secondary outcomes

  1. postoperative pain score

    Time frame: 24 hours

    NRS 0-10 point

Sponsors and collaborators

Lead sponsor

Samsun University

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Sep 28, 2022
Registry last updated
Nov 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.